NuCana plc (NCNA) Reaches $24.76 After 7.00% Up Move; Campbell & Company Investment Adviser Has Increased By $316,872 Its Trinseo S A (TSE) Stake

May 21, 2018 - By Louis Casey

Trinseo S.A. (NYSE:TSE) Logo

The stock of NuCana plc (NASDAQ:NCNA) is a huge mover today! The stock increased 4.85% or $1.14 during the last trading session, reaching $24.76. About 99,045 shares traded. NuCana plc (NASDAQ:NCNA) has 0.00% since May 21, 2017 and is . It has underperformed by 11.55% the S&P500.The move comes after 9 months positive chart setup for the $775.42M company. It was reported on May, 21 by Barchart.com. We have $26.49 PT which if reached, will make NASDAQ:NCNA worth $54.28 million more.

Campbell & Company Investment Adviser Llc increased Trinseo S A (TSE) stake by 121.01% reported in 2017Q4 SEC filing. Campbell & Company Investment Adviser Llc acquired 4,401 shares as Trinseo S A (TSE)’s stock rose 2.41%. The Campbell & Company Investment Adviser Llc holds 8,038 shares with $584,000 value, up from 3,637 last quarter. Trinseo S A now has $3.29B valuation. The stock decreased 0.13% or $0.1 during the last trading session, reaching $76.15. About 79,331 shares traded. Trinseo S.A. (NYSE:TSE) has risen 14.64% since May 21, 2017 and is uptrending. It has outperformed by 3.09% the S&P500.

NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company has market cap of $775.42 million. The firm is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. It currently has negative earnings. The firm is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology.

More recent NuCana plc (NASDAQ:NCNA) news were published by: Nasdaq.com which released: “NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors” on May 21, 2018. Also Streetinsider.com published the news titled: “NuCana (NCNA) Appoints Cyrille Leperlier to Board” on May 21, 2018. Nasdaq.com‘s news article titled: “NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences Scotland” with publication date: May 17, 2018 was also an interesting one.

More important recent Trinseo S.A. (NYSE:TSE) news were published by: Seekingalpha.com which released: “Trinseo’s Outlook Remains Positive” on May 03, 2018, also Seekingalpha.com published article titled: “Trinseo SA 2018 Q1 – Results – Earnings Call Slides”, Seekingalpha.com published: “Trinseo’s (TSE) CEO Chris Pappas on Q1 2018 Results – Earnings Call Transcript” on May 05, 2018. More interesting news about Trinseo S.A. (NYSE:TSE) was released by: Businesswire.com and their article: “Trinseo to Present at Goldman Sachs Basic Materials Conference” with publication date: May 09, 2018.

Campbell & Company Investment Adviser Llc decreased Regeneron Pharmaceuticals (NASDAQ:REGN) stake by 1,081 shares to 1,135 valued at $427,000 in 2017Q4. It also reduced Bp Plc (NYSE:BP) stake by 19,540 shares and now owns 6,488 shares. Gibraltar Inds Inc (NASDAQ:ROCK) was reduced too.

NuCana plc (NASDAQ:NCNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: